Psoriatic Arthritis

Higher risk associations also included being a current smoker and socioeconomic deprivation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.

Around 20% of participants had ultrasound evidence of at least 1 active enthesitis, and 15.7% had ultrasound signs of at least 1 active synovitis at examination.

A recent study showed an association between pediatric acute-onset neuropsychiatric syndrome and inflammatory diathesis.

A separate paper also found that the overall risk of serious infection was low in new users of targeted therapy.

A retrospective analysis compared data from the BE OPTIMAL and BE COMPLETE trials with data from pivotal trials of the IL-23–targeting therapies.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.

Subjects reported pain at the injection site was significantly reduced with the One-Press autoinjector pen and 98% chose the pen as their preferred medication delivery system.

Responders at week 104 demonstrated more significant changes from baseline and achieved normative values in PROs compared with non-responders.

Patients with inflammatory arthritis experiencing “long COVID” reported significantly worse disease activity.

Patients with lower levels of physical activity had higher levels of fatigue and a higher risk of sarcopenia.

PASI100 was achieved by 41.7% of patients at week 16 and 70.6% at week 260.

Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.

Most men (91.7%) and women (72.7%) with psoriatic arthritis exhibited sexual dysfunction.

Independent predictors of physical activity avoidance were anxiety symptoms—as determined by HADS—and the SF-36 Physical Component Score.

At the end of the intervention period, all patients displayed a significant reduction in weight of approximately 3 BMI points.

Older age and a greater BMI are associated with having a shorter interval between psoriasis and PsA diagnoses, a study found.

Patients with PsA who achieved low disease activity had a 76% - 79% improvement in the Global Assessment and Pain composite.

A study found patients with PsA have greater healthcare costs for herpes zoster than patients without PsA.

Casey Schlacher discusses the FDA approval of the new weight-based oral solution, RINVOQ LQ (upadacitinib), for treating pediatric patients with arthritis, highlighting its importance for improving patient outcomes and quality of life.

An observational study found patients with chronic inflammatory diseases who smoke may respond less to biologics than non-smokers.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

A survey shows females with PsA have a greater disease burden than males with PsA.

If approved, zasocitinib could become a leading oral treatment for PsA.